Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients

Antiviral Therapy

Volumn 16, Issue 8, 2011, Pages 1249-1257

  Chan, Henry L Y ^a   Wong, Grace L H ^a   Chim, Angel M L ^a   Chan, Hoi Yun ^a   Chu, Shirley H T ^a   Wong, Vincent W S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; DRUG MONITORING; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA CLEARANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HONG KONG; HUMANS; INTERFERON-ALPHA; LAMIVUDINE; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 83455163799     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1921     Document Type: Article

References (37)

1. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26:153-161. (Pubitemid 43668257)
2. Chan HL, Wong GL, Wong VW. A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14:489-499.
3. Chan HL, Tsang SW, Liew CT, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97:406-412. (Pubitemid 34160768)
4. Sung JJ, Chan HL, Wong ML, et al. Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002; 9:229-234. (Pubitemid 36005522)
5. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73. (Pubitemid 43042691)
6. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26:177-182.
7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539. (Pubitemid 46374607)
8. European Association for the Study of the Liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:227-242.
9. Liaw YF, Leung NW, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008; 2:263-283.
10. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136:2169-2179.
11. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
12. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588. (Pubitemid 350294224)
13. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020. (Pubitemid 43357805)
14. Hadziyannis SJ, Tassopoulos NC, Heathcote J, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751. (Pubitemid 44958517)
15. Gane E, Weilet F, Sievert W, et al. Three years efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B, preliminary analysis. 20th Conference of the Asian Pacific Association for the Study of the Liver. 25-28 March, 2010, Beijing, China. Abstract FP-019.
16. Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. 57th Annual meeting of The American Association for the Study of Liver Diseases. 27-31 October 2006, Boston, MA, USA. Abstract 114.
17. Chan HL, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12:345-353. (Pubitemid 46787979)
18. Chan HL, Wong VW, Hui AY, et al. Long term lamivudine treatment is associated with good maintained response in severe acute exacerbation of hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2006; 11:465-471. (Pubitemid 44024854)
19. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126:1750-1758. (Pubitemid 38736340)
20. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5:1462-1468. (Pubitemid 350181604)
21. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141-1150.
22. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2b for HBeAg-negative chronic hepatitis B using HbsAg and HBV DNA levels. Hepatology 2010; 52:454-461.
23. Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52:1611-1620.
24. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351:1521-1531.
25. Chan HL, Chui AK, Lau WY, et al. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68:182-187.
26. Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31:763-768. (Pubitemid 30118648)
27. Cai W, Xie Q, An B, et al. On-treatment serum HBsAg level is predictive of sustained off-treatment virological response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48:22-26.
28. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis virus markers. Hepatology 2010; 51:1933-1944.
29. Lin LY, Wong VW, Zhou HJ, et al. Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol 2010; 82:1494-1500.
30. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133:843-852. (Pubitemid 47374140)
31. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010; 52:1232-1241.
32. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128:1890-1897. (Pubitemid 40824700)
33. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12:73-82. (Pubitemid 46340428)
34. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32:1323-1331.
35. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151-1157.
36. Wiegand J, Wedemeyer H, Finger A, et al. A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther 2008; 13:547-554. (Pubitemid 352016717)
37. Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69:2167-2177.